| Literature DB >> 33712255 |
Eduardo Tobar1, Rodrigo Cornejo2, Jaime Godoy3, Mario Abedrapo4, Gabriel Cavada5, Daniel Tobar6.
Abstract
BACKGROUND: Postoperative Hyperlactatemia (PO-HL) is a frequent condition associated with poor prognosis. In recent years, there has been growing evidence that adrenergic stimulation may contribute to increased lactate levels. The use of adrenergic agonists for the control of intraoperative hypotension is frequent, and its impact on the development of PO-HL is unknown.Entities:
Keywords: Adrenergic agents; Ephedrine; Hyperlactatemia; Lactate; Phenylephrine
Mesh:
Substances:
Year: 2020 PMID: 33712255 PMCID: PMC9373707 DOI: 10.1016/j.bjane.2020.09.011
Source DB: PubMed Journal: Braz J Anesthesiol ISSN: 0104-0014
Figure 1Flowchart of the study. Evaluated, excluded, and included patients.
Figure 2Postoperative lactate levels on time, by groups Hyperlactatemia (HL) and not Hyperlactatemia (nHL), mean ± SD.
Figure 3Postoperative lactate levels over time, by gender (a); anesthetic time (b); ephedrine group (c); and ScvO2 group (d), mean ± SD.
Comparison of baseline and intraoperative characteristics in the Early-onset Hyperlactatemia group (eHL), Late-onset Hyperlactatemia group (LHL), and non-Hyperlactatemia (nHL) groups; mean ± SD.
| nHL (n = 11) | eHL (n = 3) | LHL (n = 14) | |
|---|---|---|---|
| Lactate baseline | 1.0 ± 0.3 | ||
| Lactate peack (mEq.L-1) | 1.2 ± 0.4 | 3.0 ± 0.4 | 3.9 ± 1.4 |
| Female gender (%) | 36 | 67 | 79 |
| Age (y.o.) | 73 ± 6 | 76 ± 5 | 73 ± 9 |
| Hypertension (%) | 45 | 33 | 71 |
| Diabetes (%) | 27 | 33 | 36 |
| Surgical time | 125 ± 40 | 180 ± 73 | 177 ± 67 |
| Anesthetic time | 182 ± 39 | 222 ± 78 | 241 ± 68 |
| Intraoperative fluids (mL) | 1845 ± 1154 | 2416 ± 1233 | 854 ± 831 |
| Total ephedrine doses (mg) | 18 ± 16 | 32 ± 33 | 54 ± 23 |
| Total phenilephrine doses (mg) | 171 ± 299 | 500 ± 866 | 721 ± 1560 |
| Norephinephrine use | 18 | 33 | 29 |
| MAP iop (mmHg) | 79 ± 8 | 75 ± 2 | 76 ± 6 |
| ScvO2 intraoperatoria | 86 ± 5 | 76 ± 10 | 78 ± 7b |
nHL, non-Hyperlactatemia patients; eHL, early-onser Hyperlactatemia patients; LHL, Late-onset Hyperlactatemia patients; MAP iop, intra-operative Mean Arterial Pressure; ScvO2, Central Venous Oxygen Saturation.
p < 0.05 between nHL and Ehl.
p < 0.05 between nHL and eHL.
Multilevel mixed-effects linear regression analyses, with univariate and multivariate analysis.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Coef | 95% CI | Coef | 95% CI | |||
| Gender | 0.270 | −0.301–0.841 | 0.354 | |||
| Anesthetic time | 0.005 | 0.001–0.009 | 0.014 | 0.099 | −0.220–0.418 | 0.543 |
| Ephedrine | 0.014 | 0.004–0.024 | 0.004 | 0.012 | 0.003–0.019 | 0.004 |
| MAP iop | −0.031 | −0.071–0.009 | 0.136 | −0.028 | −0.052– -0.034 | 0.026 |
| Phenilephrine | 0.000 | 0.000–0.000 | 0.001 | 0.000 | 0.000–0.000 | 0.001 |
| Norepinephrine | 0.331 | −0.310–0.973 | 0.311 | |||
| ScvO2 | −0.016 | −0.053–0.021 | 0.401 | |||
MAP iop, intra-operative Mean Arterial Pressure; ScvO2, Central Venous Oxygen Saturation.
p < 0.05.